Long non-coding RNAs (lncRNAs) are RNA molecules longer than 200 nucleotides that do not code for proteins but regulate gene expression through diverse mechanisms. Once considered "genomic noise," lncRNAs have emerged as critical regulators of neuronal development, synaptic plasticity, and neurodegeneration. Dysregulation of lncRNAs contributes to the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (FTD), Huntington's disease (HD), and other neurodegenerative disorders.
This pathway page covers the major lncRNAs implicated in neurodegeneration, their molecular mechanisms, and therapeutic targeting strategies.
Nuclear lncRNAs primarily regulate gene transcription through chromatin remodeling and transcriptional interference.
- NEAT1 (Nuclear Enriched Abundant Transcript 1): Forms nuclear paraspeckles, regulates gene expression by sequestering transcription factors. Upregulated in AD and ALS, involved in DNA damage response and stress granule dynamics.
- MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1): Regulates synaptic plasticity, alternative splicing, and neuronal differentiation. Dysregulated in AD (affecting APP processing) and PD.
- XIST (X-inactive specific transcript): Regulates X-chromosome inactivation. May contribute to sex-biased neurodegeneration patterns.
- HOTAIR (HOX Transcript Antisense RNA): Regulates HOX gene clusters, promotes chromatin silencing. Elevated in AD brains, affects tau pathology.
- MEG3 (Maternally Expressed Gene 3): Tumor suppressor lncRNA with neuroprotective properties. Reduced in AD and PD.
Cytoplasmic lncRNAs regulate mRNA stability, translation, and protein function.
- BC200 (Brain Cytoplasmic RNA 200): Regulates dendritic translation at synapses. Overexpressed in AD, correlates with cognitive decline.
- BACE1-AS (BACE1 Antisense Transcript): Regulates BACE1 (beta-secretase) expression. Elevated in AD, promotes amyloid-beta production.
- GDNFOS (GDNF Opposite Strand): Regulates GDNF (Glial Cell Line-Derived Neurotrophic Factor) expression. Relevant to PD.
- AS UCHL1: Antisense transcript of ubiquitin C-terminal hydrolase L1, regulates PARK5 gene. Implicated in PD.
- BACE1-AS: The most well-characterized AD-related lncRNA. BACE1-AS enhances BACE1 mRNA stability, increasing beta-secretase activity and amyloid-beta production. Knockdown reduces amyloid burden in mouse models.
- APP-AS: Antisense transcript of APP gene. Regulates APP processing and may influence amyloidogenesis.
- lncRNA-171F: Regulates amyloid precursor protein processing through unknown mechanisms.
- HOTAIR: Elevated in AD brain, promotes tau hyperphosphorylation through epigenetic mechanisms.
- NEAT1: Paraspeckle formation affected in AD, influences tau pathology progression.
- LINC00672: Reduced in AD, associated with tau phosphorylation.
- BC200: Overexpressed in AD temporal lobe, reduces local translation at dendritic spines.
- MALAT1: Regulates synapse-related gene expression, altered in AD.
- lncRNA-NEAT1: Affects synaptic protein synthesis.
- AS_SNCA: Antisense transcript of SNCA (alpha-synuclein gene). Regulates SNCA expression, contribute to Lewy body formation.
- HOTAIR: Elevated in PD substantia nigra, affects dopaminergic neuron survival.
- MEG3: Reduced in PD, associated with increased neuronal apoptosis.
- LINC00341: Regulates mitochondrial dynamics, altered in PD.
- lncRNA-ATB: Regulates autophagy and mitophagy, relevant to PD pathology.
- NEAT1: Promotes neuroinflammation in PD through NF-κB signaling.
- MALAT1: Regulates microglial activation and inflammatory responses.
¶ lncRNAs in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)
- NEAT1: Essential for paraspeckle formation, altered in ALS/FTD with TDP-43 pathology.
- TARDP-1: C9orf72 antisense transcript, contributes to toxic dipeptide repeat protein production.
- C9orf72-AS (antisense): Bidirectional transcription produces toxic repeat RNAs and proteins.
- lncRNA-EPF: Regulates ellipsoid body formation, implicated in Drosophila ALS models.
- MALAT1: Altered splicing regulation in ALS motor neurons.
- XIST: Dysregulated in female ALS patients (X-chromosome linked vulnerability).
- HTT (antisense): Regulates mutant huntingtin expression.
- NEAT1: Elevated in HD, affects transcriptional dysregulation.
- lncRNA-HD: Directly interacts with huntingtin protein, influences aggregation.
- DGCR5: Reduced in HD, affects microRNA processing.
flowchart TD
AlncRNA["AlncRNA Dysregulation"] --> B["Chromatin Remodeling"]
A --> C["Transcriptional Regulation"]
A --> D["Post-Transcriptional Control"]
A --> E["Protein Interaction"]
B --> B1["Histone Modification<br/>DNA Methylation"]
B --> B2["Chromatin Complex Recruitment<br/>PRC2, CoREST"]
C --> C1["Promoter/Enhancer Binding<br/>Transcription Factor Sequestration"]
C --> C2["Decoy Function<br/>Sponging TFs"]
D --> D1["mRNA Splicing<br/>Alternative Splicing"]
D --> D2["mRNA Stability<br/>Decay Regulation"]
D --> D3["Translation Control<br/>Ribosome Recruitment"]
E --> E1["Protein Tethering<br/>Localization"]
E --> E2["Enzyme Activity Modulation<br/>Kinases, Deacetylases"]
B1 --> F1 ["Neurodegeneration"]
B2 --> F1
C1 --> F1
C2 --> F1
D1 --> F1
D2 --> F1
D3 --> F1
E1 --> F1
E2 --> F1
F1 --> G["Amyloid Pathology"]
F1 --> H["Tau Pathology"]
F1 --> I["Synaptic Dysfunction"]
F1 --> J["Mitochondrial Dysfunction"]
F1 --> K["Neuroinflammation"]
F1 --> L["Apoptosis"]
- BACE1-AS ASOs: In development for AD, reduce amyloid production.
- ASO-mediated NEAT1 knockdown: Potential for ALS/FTD.
- C9orf72-targeted ASOs: In clinical trials for ALS/FTD.
- HDAC inhibitors: Indirectly modulate lncRNA expression (e.g., MALAT1, HOTAIR).
- BET inhibitors: Affect lncRNA transcription regulation.
- CRISPRi: Knockdown of pathogenic lncRNAs.
- CRISPRa: Activate protective lncRNAs.
- Base editing: Correct disease-associated lncRNA variants.
- lncRNA mimics: Restore lost protective lncRNA function.
- lncRNA sponges: Sequester pathogenic microRNAs.
- BACE1-AS: Detectable in blood and CSF, elevated in AD.
- NEAT1: Detectable in blood, elevated in ALS/FTD.
- GDNFOS: Potential PD biomarker.
- BC200: Correlates with cognitive decline severity in AD.
- HOTAIR: Associated with disease progression in PD.
- lncRNA signatures: May track treatment response.
- lncRNA ratios: BC200/BC1 ratio as progression marker.
| lncRNA | Disease | Function | Therapeutic Potential |
|--------|---------|----------|---------------------|
| BACE1-AS | AD | Increases BACE1, Aβ production | ASO target |
| NEAT1 | ALS/FTD | Paraspeckle formation, stress response | ASO target |
| MALAT1 | AD/PD | Synaptic regulation, splicing | Modulator target |
| HOTAIR | AD/PD | Chromatin silencing | HDAC inhibitors |
| AS_SNCA | PD | Regulates α-synuclein | ASO target |
| C9orf72-AS | ALS/FTD | Toxic repeat production | ASO target |